Irradiated blood products: Difference between revisions
From IDWiki
Content deleted Content added
Imported from text file |
No edit summary |
||
| Line 1: | Line 1: | ||
== Indications == |
|||
* Patients undergoing bone marrow or stem cell transplants |
* Patients undergoing bone marrow or stem cell transplants |
||
** Continue until immunosuppression is discontinued |
** Continue until immunosuppression is discontinued |
||
* Patients treated with purine analogs (fludarabine), purine antagonists (bendamustine), alemtuzumab, and anti-thymocyte globulin |
* Patients treated with purine analogs ([[fludarabine]]), purine antagonists ([[bendamustine]]), [[alemtuzumab]], and [[anti-thymocyte globulin]] |
||
* Patients with Hodgkin lymphoma |
* Patients with [[Hodgkin lymphoma]] |
||
* Recipients of directed transfusions from family members |
* Recipients of directed transfusions from family members |
||
* Recipients of HLA-matched platelets |
* Recipients of HLA-matched platelets |
||
Latest revision as of 14:22, 30 June 2025
Indications
- Patients undergoing bone marrow or stem cell transplants
- Continue until immunosuppression is discontinued
- Patients treated with purine analogs (fludarabine), purine antagonists (bendamustine), alemtuzumab, and anti-thymocyte globulin
- Patients with Hodgkin lymphoma
- Recipients of directed transfusions from family members
- Recipients of HLA-matched platelets
- Severe T-cell congenital immunodeficiency states
- Intrauterine transfusion (IUT)
- Neonatal exchange transfusions for infants with prior IUT
- Neonatal top-up transfusion if there has been a previous IUT
